102152-03-4

Basic information

• Product Name: 1H-Imidazole-2-methanol, 1-(triphenylmethyl)-
• Synonyms: 2-hydroxymethyl-1-trityl-1H-imidazole;(1-trityl-1H-imidazol-2-yl)-methanol;1-triphenylmethyl-1H-imidazole-2-methanol;2-Hydroxymethyl-1-tritylimidazole;2-(hydroxymethyl)-1-tritylimidazole;2-hydroxymethyl-1-triphenylmethylimidazole
• CAS NO: 102152-03-4
• Molecular Formula: C23H20N2O
• Molecular Weight: 340.425
• Mol File: 102152-03-4.mol
• Article Data: 9

Chemical Properties

• Melting Point: 243-244 °C
• Boiling Point: 470.0±33.0 °C(Predicted)
• Density: 1.10±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 1H-Imidazole-2-methanol, 1-(triphenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Imidazole-2-methanol, 1-(triphenylmethyl)-(102152-03-4)
• EPA Substance Registry System: 1H-Imidazole-2-methanol, 1-(triphenylmethyl)-(102152-03-4)

Safety Data

• Hazardous Substances Data: 102152-03-4(Hazardous Substances Data)

Upstream product

• 15469-97-3 N-tritylimidazole 
• 76-83-5 trityl chloride 
• 7732-18-5 water 
• 102210-86-6 2-Carbomethoxy-1-tritylimidazole 
• 67478-50-6 1-(triphenylmethyl)-1H-imidazole-2-carboxaldehyde 
• 67478-49-3 1-trityl-1H-imidazole-2-carboxylic acid ethyl ester 

Downstream Products

• 1200497-50-2 C₂₈H₂₂N₄O₃ 
• 960412-69-5 2-methoxymethyl-1-trityl-1H-imidazole 
• 759443-19-1 2-chloromethyl-1-trityl-1H-imidazole 
• 76-84-6 triphenylmethyl alcohol 
• 499214-81-2 2-(fluoromethyl)-1-trityl-1H-imidazole 

Relevant articles and documents

HYDROXAMATE COMPOUNDS AS ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR

The present invention relates to compounds of formula I shown below: (I) wherein R1, R2 and R3 are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or conditions in which adenosine A2a receptor activity is implicated, such as, for example, cancer.

Synthesis, structure-activity relationship studies, and identification of novel 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 1

A novel series of non-peptidic OX1R/OX2R orexin receptor antagonists was prepared by heterocyclic replacement of the dimethoxyphenyl moiety contained in the tetrahydroisoquinoline core skeleton of almorexant. Introduction of substituted imidazole moieties delivered potent dual orexin receptor antagonists with nanomolar potency for hOX1R and hOX2R suitable for further fine-tuning. The preparation of these novel orexin receptor antagonists and the outcome of preliminary structure-activity relationship studies are described in this communication.

5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES

The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I),wherein X represents CH2 or O; R1 represents a phenyl group, which group is independently mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, cyano, trifluoromethoxy and trifluoromethyl; R2 represents (C1-4)alkyl, (C1-4)alkoxy, (C2-4)alkenyl, halogen, cyano, hydroxymethyl, trifluoromethyl, C(O)NR5R6 or cyclopropyl; R3 represents (C1-4)alkyl, (C1-4)alkoxy-methyl or halogen; R4 represents (C1-4)alkyl; R5 represents hydrogen or (C1-4)alkyl; and R6 represents hydrogen or (C1-4)alkyl. The invention also relates to pharmaceutically acceptable salts of such compounds; and to the use of such compounds as medicaments; especially as orexin receptor antagonists.